10-K: Donaldson Reports FY25 Earnings Decline Amid Impairments

Donaldson Company, Inc. reported a decrease in net earnings and diluted EPS for fiscal year 2025, primarily due to a significant impairment charge in its Life Sciences segment.

Summary

• Net sales for fiscal year 2025 increased by 2.9% to $3,690.9 million, up from $3,586.3 million in fiscal year 2024.
• Net earnings decreased by 11.3% to $367.0 million in fiscal year 2025, compared to $414.0 million in fiscal year 2024.
• Diluted earnings per share (EPS) fell to $3.05 in fiscal year 2025 from $3.38 in fiscal year 2024, a 9.8% decrease.
• Gross margin as a percentage of net sales declined to 34.8% in fiscal year 2025 from 35.5% in fiscal year 2024, primarily due to higher manufacturing costs and tariff-related inflation.
• A $62.0 million loss on impairment of intangible assets was recorded in fiscal year 2025, impacting the Life Sciences segment.
• Operating income decreased by 9.0% to $495.4 million in fiscal year 2025, down from $544.1 million in fiscal year 2024.
• Research and development expenses decreased by 6.2% to $87.8 million, representing 2.4% of net sales, due to focused project prioritization.
• Cash provided by operating activities decreased by $73.7 million to $418.8 million, driven by higher working capital requirements and income tax payment timing.
• Total debt increased by $131.6 million to $668.3 million, raising the debt-to-capitalization ratio to 31.5% from 26.5% in the prior year.
• The company repurchased 4.9 million shares for $333.6 million in fiscal year 2025 and paid dividends of $1.11 per common share.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to a significant decline in net earnings and EPS, coupled with a substantial impairment charge in a strategic growth segment (Life Sciences). While sales saw modest growth and some segments performed well, the overall profitability decline, increased debt, and specific underperformance in acquired assets weigh heavily. Positive aspects like increased dividends and share repurchases are overshadowed by the core financial performance issues and strategic setbacks.

Positives

• Net sales increased by 2.9% year-over-year, reaching $3,690.9 million.
• The Life Sciences segment saw a significant increase in earnings before income taxes, moving from a loss of $10.4 million in fiscal 2024 to a gain of $4.4 million in fiscal 2025, driven by higher volume, restructuring benefits, and a $4.0 million reduction in contingent consideration liability.
• Aftermarket sales within the Mobile Solutions segment increased by $90.7 million, reflecting solid market demand and market share gains.
• Aerospace and Defense sales within the Industrial Solutions segment increased by $24.8 million, indicating ongoing strength in these end markets.
• Selling, general and administrative expenses as a percentage of net sales decreased to 17.4% from 17.8%, attributed to disciplined expense management and a $4.0 million benefit from the Purilogics contingent consideration liability reduction.
• The company extended its $500.0 million revolving credit facility to $600.0 million and extended its maturity date to June 12, 2030, enhancing liquidity and capital resources.
• Donaldson repurchased 4.9 million shares for $333.6 million in fiscal 2025, demonstrating a commitment to returning capital to shareholders.
• Dividends paid increased to $1.11 per common share in fiscal 2025 from $1.02 in fiscal 2024.

Negatives

• Net earnings decreased by 11.3% to $367.0 million in fiscal year 2025.
• Diluted EPS decreased by 9.8% to $3.05 in fiscal year 2025.
• A significant loss on impairment of intangible assets of $62.0 million was recorded, primarily affecting the Life Sciences segment's Univercells Technologies ($46.6 million) and Solaris ($15.4 million) due to lower-than-anticipated bioprocessing capital spending and declining market demand for industrial bioreactors.
• Gross margin decreased by 0.7 percentage points to 34.8%, mainly due to higher manufacturing costs from footprint optimization and tariff-related LIFO inventory inflation.
• Operating income decreased by 9.0% to $495.4 million.
• Off-Road and On-Road net sales decreased by $21.3 million and $29.2 million, respectively, due to weak global equipment production and end market conditions in transportation and agriculture.
• Cash provided by operating activities decreased by $73.7 million, indicating higher working capital requirements and timing of income tax payments.
• Cash used in investing activities increased by $63.5 million, primarily due to a $71.2 million equity method investment in Medica.
• Total debt increased by $131.6 million, leading to a higher debt-to-capitalization ratio of 31.5% from 26.5%.

Risks

• Global operations are subject to political and military events, tariffs, trade barriers, legal and regulatory requirements, difficulties in staffing, credit risk of local customers, economic deterioration (including inflation), and challenges in protecting intellectual property.
• Potential new or incremental tariffs could disrupt supply chains, increase costs, and make products less competitive, with an expected annual cost of approximately $35 million from existing tariffs.
• Unexpected events like natural disasters, climate-related events, pandemics, or civil unrest could disrupt operations, increase costs, and impact the ability to meet customer demand.
• Supply chain disruptions, unavailable raw materials, significant demand fluctuations, and material cost changes (e.g., steel, filter media, petrochemicals) could impact sales and cost of sales.
• Inability to attract, engage, train, and retain qualified personnel, especially in new technologies, could adversely affect success due to competition for talent and labor shortages.
• Complexity of manufacturing operations could lead to an inability to meet demand, longer lead times, and loss of customers if capacity cannot be adjusted or product quality is compromised.
• Operating in highly competitive markets with numerous competitors requires consistent investment in R&D, sales, marketing, and customer service, with uncertain returns on these investments.
• Disruptive technologies, such as the wider adoption of alternative power solutions (e.g., electrification of equipment), could reduce or eliminate demand for existing products.
• Exposure to customer concentration in cyclical industries (e.g., construction, agriculture, mining, oil and gas, transportation) makes sales vulnerable to economic conditions in these sectors.
• Failure to successfully manage productivity improvements may prevent the realization of expected benefits and cost savings.
• Inability to achieve sustainability commitments and targets could negatively impact reputation and performance.
• Acquisitions, divestitures, and other strategic transactions carry risks such as integration inefficiencies, debt incurrence, contingent liabilities, loss of key customers/employees, and diversion of management's attention.
• Vulnerability of information technology systems and security to cybersecurity threats could lead to compromise of confidential information, data manipulation, production downtimes, and operational disruptions.
• Challenges in protecting and enforcing intellectual property rights across jurisdictions, including patent expiration and litigation risks, could affect competitive advantage.
• Costs associated with lawsuits, investigations, or complying with evolving governmental laws and regulations (e.g., environmental, data protection, privacy) could materially impact financial results.
• Unfavorable fluctuations in foreign currency exchange rates pose transactional and translational risks, impacting net sales and net earnings.
• Changes in capital and credit markets may negatively affect the ability to access financing to support strategic initiatives, and existing debt covenants could restrict financial flexibility.

Future Outlook

The company expects cash paid for capital expenditures in fiscal 2026 to be between $65 million and $85 million, primarily for capacity expansion, new products and technologies, and maintaining existing assets. It also anticipates future restructuring costs of $5.0 million to $10.0 million through fiscal 2026. The company believes its liquidity from operating activities, existing cash, and credit facilities will be sufficient to meet cash requirements for the next 12 months and beyond, including working capital, debt service, capital expenditures, dividends, share repurchases, and potential acquisitions. The company continues to evaluate the impact of the OECD's Pillar Two global minimum tax rules but does not expect a material impact on its financial statements.

Management Comments

• Our purpose is to advance filtration for a cleaner world.
• We have three primary strategic priorities to drive profitable growth: Extend Market Access, Expand Technologies and Solutions, and Pursue Strategic Acquisitions.
• We strive to recover or offset all material cost increases through selective price increases to our customers and our cost reduction initiatives, which include material substitution, process improvement and product redesigns.
• We believe that our market diversification between the regions and various end markets it serves and diversification through its OEM and replacement parts customers has helped to limit the impact of weakness in any one product line, market or geography on the consolidated operating results of the Company.
• We are closely monitoring the evolving trade landscape, as well as our ability to mitigate the impact of tariffs and our analysis of the potential impact. While the ultimate impact of tariffs remains uncertain, we continue to expect annual costs related to recently implemented or increased tariffs of approximately $35 million, which represents less than 1% of our total sales and is expected to be largely offset by pricing increases.
• We are committed to the health, wealth and work-life balance of employees and offers competitive financial compensation packages that may include both base pay and bonus elements in addition to competitive benefits packages to help support individuals and their families.

Industry Context

Donaldson operates in highly competitive filtration markets across Mobile Solutions, Industrial Solutions, and Life Sciences. The company's performance reflects broader industry trends, including strong demand in aftermarket services, aerospace and defense, disk drive, and food and beverage sectors. However, it also highlights challenges in global equipment production, particularly in off-road and on-road markets, and lower-than-anticipated bioprocessing capital spending, which impacted its Life Sciences segment. The company's strategic priorities, including expanding into bioprocessing and alternative power solutions, align with industry shifts towards sustainability and advanced technologies. The ongoing impact of tariffs and global economic conditions continues to influence supply chains and operational costs across the industry.

Comparison to Industry Standards

• The company believes it is a market leader within many of its product lines, specifically within its Off-Road and On-Road product lines for OEMs and in the Aftermarket business for replacement filters, indicating strong competitive positioning in these areas.
• The Mobile Solutions segment's principal competitors include several large global competitors and many regional competitors, especially in the Aftermarket business, suggesting a fragmented but competitive landscape.
• The Industrial Solutions segment's principal competitors vary from country to country and range from large global competitors to a significant number of smaller competitors, indicating diverse competitive pressures.
• The Life Sciences segment's principal competitors include several large global competitors as well as niche players, reflecting a specialized and competitive market.
• The impairment of Univercells Technologies and Solaris assets in the Life Sciences segment, due to lower-than-anticipated bioprocessing capital spending and declining market demand for industrial bioreactors, suggests that these specific ventures may have underperformed relative to initial market expectations or industry growth rates in their niche areas, though no specific comparable companies or projects are named in the filing.

Management Changes

Corporate Governance

Legal Proceedings

• The company records provisions when a liability is probable and estimable, reviewing claims and litigation quarterly. Estimated liabilities are considered adequate and appropriate.
• It is believed to be remote that the settlement of any currently identified claims or litigation will materially exceed what is accrued.

Related Party Transactions

• The company has an unconsolidated joint venture, Advanced Filtration Systems Inc. (AFSI), with Caterpillar Inc., where both companies equally own shares and guarantee certain debt and banking services. Donaldson guarantees half of AFSI's outstanding debt, which was $43.9 million as of July 31, 2025.
• The company holds a non-controlling 49% stake in Medica S.p.A., acquired for $67.9 million, accounted for under the equity method. The company has an option to acquire the remaining 51% stake in three years.
• The company is also party to a joint venture with PT Panata Jaya Mandiri.

Stakeholder Impact

• Shareholders: Experienced a decrease in net earnings and diluted EPS, but also benefited from increased dividends and significant share repurchases. The increase in total debt and impairment charges could be a concern for long-term value.
• Employees: Affected by restructuring activities, which included severance charges. The company emphasizes providing competitive compensation, benefits, and learning opportunities, and fostering a diverse and safe workplace.
• Customers: Benefit from the company's focus on technology-led filtration products and solutions, with strong demand in Aftermarket, Disk Drive, Food & Beverage, and Aerospace & Defense. However, customers in Off-Road and On-Road markets faced weak end market conditions.
• Suppliers: Subject to the company's efforts to manage raw material costs and supply chain volatility, with tariffs posing an ongoing cost factor.
• Creditors: The company's increased total debt and debt-to-capitalization ratio indicate higher leverage, though the company remains in compliance with debt covenants and has extended credit facilities.

Next Steps

• Continue global footprint and cost optimization actions, with estimated future costs of $5.0 million to $10.0 million through fiscal 2026.
• Evaluate the impact of new or amended environmental laws, regulations, or requirements.
• Monitor and adapt to evolving privacy, data protection, and data security laws and regulations.
• Continue to evaluate the impact of OECD Pillar Two proposals on tax laws and regulations.
• The company has an option to acquire the remaining 51% stake in Medica S.p.A. in three years.

Key Dates

Recommendation

The filing presents a mixed financial picture for Donaldson Company, Inc. While net sales saw modest growth and the Life Sciences segment showed an improvement in earnings (albeit after a significant impairment), the overall decline in net earnings and diluted EPS, coupled with a substantial $62.0 million impairment charge, indicates underlying challenges. The increase in total debt and the decline in gross margin are also concerning. However, the company's continued share repurchases and increased dividends demonstrate a commitment to shareholder returns, and some segments like Aftermarket and Aerospace & Defense show strength. The strategic investment in Medica and ongoing restructuring efforts could position the company for future growth, but the immediate financial performance and specific issues in bioprocessing warrant caution. A 'hold' recommendation is appropriate as investors should monitor the effectiveness of restructuring, the performance of the Life Sciences segment post-impairment, and the impact of macroeconomic factors on key end markets before making further investment decisions.

Keywords

Filtration, Industrial Solutions, Mobile Solutions, Life Sciences, SEC Filing, 10-K, Annual Report, Financial Results, Earnings, EPS, Impairment, Bioprocessing, Share Repurchase, Dividends, Debt, Corporate Governance, Risk Factors, Donaldson Company